doi:10.1111/pcmr.12167
The key to this process is that it is gradual, medically supervised, and, most importantly, personalized to you
Linzess is FDA-approved to treat irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) in adults, and functional constipation in children ages 617
Journal of the American Academy of Dermatology , 59(3), AB122
However, the most suitable treatment depends on individual factors such as medical history, medication tolerance, and clinician guidance
Il est de 146,91 pour 1 mois de traitement la dose la plus faible de 0,25 mg et de 195,10 la dose la plus leve de 2,4 mg